Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients

Prostate Cancer Clinical Trial

Official title:

Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A In A Gel Applied in Patients That Performed Radical Prostatectomy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05558007
• Other study ID #: BZ371CLI004
• Status: Recruiting
• Phase: Phase 2
• Start date: November 22, 2023
• Est. completion date: September 2024

Study information

• Verified date: March 2024
• Source: Biozeus Biopharmaceutical S.A.
• Contact: Camilla NR Trindade, PhD
• Phone: +55(21)2523-9089
• Email: camilla.nunes[@]biozeus.com.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.

Description:

Prostate cancer remains one of the most prevalent cancer in men. For its treatment, recent technological advances demonstrate that the most effective treatment is the Radical Prostatectomy (RP) procedure. However, although curative for Prostate Cancer, can result in damage to the cavernosal nerves. The cavernosal autonomic nerves travel posterolaterally to the prostate to enter the penis and regulate blood flow and hence erection. Thus, damage caused by RP will affect NO tissue release and blood flow regulation, causing erectile dysfunction. BZ371A has the ability to restore local blood flow regulation by a new and innovative mechanism of action and, therefore, has potential to be a supportive therapy for RP patients (restoring the erectile function). Thus, this study aims to evaluate efficacy, safety and tolerabilty of BZ371A on the recovery of erectile function of patients that were underwent Radical Prostatectomy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: September 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Men between the ages of 40 and 65 years;

2. Exclusive heterosexual men, regardless of race or social class.

3. RP due to prostate cancer without metastasis;

4. RP performed less than 60 days before the screening visit;

5. Erectile function prior to normal RP, defined as IIEF questionnaire with more than 22 points in domain A;

6. Stable sexual partner (more than 2 months prior to RP), and intention to maintain the relationship during the study.

7. Continuous use of 5mg Tadalafil from the 30th up to the 60th day after RP.

Exclusion Criteria:

1. Prostate cancer in TNM stage classified as T3 or T4.

2. Perineal and/or open RP;

3. Necessity of other therapy for prostate cancer than RP, including radiation therapy or hormone therapy;

4. Uncontrolled diabetes at screening visit (HbA1C > 10%);

5. Prior spinal cord injury with lower limb paralysis;

6. Current male hormone use, or hypogonadism, defined by total testosterone below 8 nmol/L (2300 pg/mL) or total testosterone between 8 and 11 nmol/L (2300 and 3170 pg/mL) and free testosterone < 220 pmol/L (< 64 ng/dL);

7. Patients with current depression, characterized by use or need for use of antidepressants.

8. Presence of genital lesions (such as severe penile fibrosis or Peyronie's disease) or active sexually transmitted disease (STD) (such as herpes, gonorrhea, candidiasis, HPV, and others) that impair analysis of local adverse effects on the genitalia;

9. Use of topical medications in the genital region that may interfere in the IP evaluation, as well as in its absorption or drug interaction;

10. Possession of penile prosthesis;

11. History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patient with heart diseases (including history of angina and/or heart failure) and nephropathies;

12. Current use of nitrates, such as propatilnitrate (Sustrate®), isosorbide (Monocordil®, Cincordil®, Isordil®), nitroglycerin (Nitradisc®, Nitroderm TTS®, Nitronal®, Tridil®) and isosorbitol dinitrate (Isocord®);ketoconazole; ritonavir; and rifampicin.

13. Findings on ECG and/or laboratory tests that, in the Investigator's criteria, are considered significant and offer risk to the research volunteer's participation or may hinder the study analyses;

14. BP outside the limits considered safe: SBP below 90 mmHg or above 170 mmHg; or DBP below 50 mmHg or above 100 mmHg, except situations such as "white coat syndrome";

15. Diseases that can cause priapism, such as sickle cell anemia, multiple myeloma, or leukemia;

16. Histroy of priapism, defined as painful erection from up to 6 hours.

17. Current relevant diarrhea, defined as duration over four weeks, association with abdominal pain or dysabsortive syndrome, or presence of mucus, pus, or blood in the stool;

18. Known hypersensitivity to tadalafil and/or BZ371A;

19. History of symptomatic Lactose intolorence such as: the necessity of enzymatic treatment, abdominal distension or diarrhea when ingesting products or supplements with lactose;

20. Low adhsesion to 5mg Tadalafil use, characterized by the use of <80% of the pills between the 30th and 60th day post PR;.

21. Pregnant or lacting partner.

22. Partner in childbearing age which does not accept to get exposed to the treatment

23. Any disease, condition or physical finding that the Investigator considers significant and that increases the risk of the research subject's participation or may interfere with the results, including severe debilitating illness, presence of cancer other than prostate cancer, severe mental illness persistent medication abuse;

Related Conditions & MeSH terms

• Erectile Dysfunction
• Erectile Dysfunction Following Radical Prostatectomy
• Prostate Cancer
• Prostatic Neoplasms
• Radical Prostatectomy

Intervention

Drug:
• Tadalafil 5mg
Daily oral administration of tadalafil 5mg
• BZ371A
Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL
• Oral Placebo
Oral administration of a placebo pill
• Topical Placebo
Topical application of 1.5 mL of placebo

Locations

Country	Name	City	State
Brazil	Hospital Urológica	Belo Horizonte

Sponsors (1)

Lead Sponsor	Collaborator
Biozeus Biopharmaceutical S.A.

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Assisted Erectile Function	Measurement of the ability to to have an erection that allows sexual intercourse, under use of medication. This will be assessed by using the IIEF questionnaire, domain A (erectile function section) (IIEF-EF).	From up to 30 days before Baseline, Baseline, 30 days, 60 days
Secondary	Change in successful vaginal intercourse rate	Rate of successful vaginal intercourse will be assessed through question 3 of the SEP (Sexual Encouter Profile) questionnaire.	From up to 30 days before Baseline, Baseline, 30 days, 60 days
Secondary	Change in quality of sexual intercourse	Quality of sexual intercourse, through the EDITS questionnaire (Erectile Dysfunction Inventory of Treatment Satisfaction);	30 days, 60 days
Secondary	Change in penile extension	Penile extension, measured with a ruler.	Baseline, 30 days, 60 days
Secondary	Penile Blood flow increase	Increased blood flow, assessed by peak systolic velocity (PSV), end-diastolic velocity (EDV) and resistivity index (RI) assessed by Doppler examination;	From up to 30 days before Baseline, Baseline, 30 days, 60 days
Secondary	Adverse effects report	Adverse effects evaluation of compound use and application	Baseline 30 days, 60 days and 75 days
Secondary	Physical examination of the applied region	Number of participants with abnormal physical exam findings in the applied region	From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days
Secondary	Change in SBP	Change in Systolic Blood Pressure	From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days
Secondary	Change in DBP	Change in Diastolic Blood Pressure	From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days
Secondary	Change in Heart Rate (HR)	Change in Heart Rate	From up to 30 days before Baseline, Baseline, 30 days, 60 days and 75 days
Secondary	Basal chest electrocardiogram (ECG).	Number of participants with abnormal ECG test results	From up to 30 days before Baseline, 30 days and 60 days
Secondary	Blood evaluation	Number of participants with abnormal laboratory test results	From up to 30 days before Baseline, and 60 days
Secondary	Urine evaluation	Number of participants with abnormal laboratory test results	From up to 30 days before Baseline, and 60 days